Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement
MT Newswires Live
Dec 19
Mirum Pharmaceuticals (MIRM) said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.
The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay Therapeutics.
The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.